Meeting
2022 ASCO Annual Meeting
Discovery and clinical validation of cost-effective noninvasive early detection of hepatocellular carcinoma (HCC) through circulating tumor DNA (ctDNA) methylation signature.
Authors
Xin-Rong Yang
Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China
Xin-Rong Yang , Rui Liu , Jian Zhou , Jia Fan , De-Zhen Guo , Ao Huang , Yingchao Wang , Zhixiong Cai , Hui Wang , Qichang Yang , Zhixi Su , Chengcheng Ma , Minjie Xu , Wei Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4103)
DOI
10.1200/JCO.2022.40.16_suppl.4103
Abstract #
4103
Poster Bd #
90
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
DNA methylation patterns between tissue and blood samples in ovarian cancer.
First Author: Hao Wen
Poster
2022 ASCO Annual Meeting
Early detection of hepatocellular carcinoma using cfDNA signatures from cirrhotic patients with nodules.
First Author: Rong Fan
Poster
2024 ASCO Annual Meeting
Leveraging cfDNA fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma.
First Author: Zichen Jiao
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
First Author: Feng Wen